Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial
Authors not listed
Innostellar Biotherapeutics Co.,Ltd · 2026
Abstract
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 48 and 56.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Anonymous. (2026). A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial. <em>Innostellar Biotherapeutics Co.,Ltd</em>. https://clinicaltrials.gov/study/NCT07317934
Vancouver
Anonymous. A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial. Innostellar Biotherapeutics Co.,Ltd. 2026.
BibTeX
@misc{anon2026APhase,
title = {A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial},
author = {Anonymous},
journal = {Innostellar Biotherapeutics Co.,Ltd},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.